Stacey Cohen, MD
Stacey Shiovitz

Stacey A. Cohen                                                                                                                                                      Page 1


Stacey A. Cohen                                          September 5, 2017


825 Eastlake Ave E., G4-830, Seattle, WA 98109-1023

Desk: (206) 288-6658 [preferred], Cell: (206) 552-4929

Email: [preferred]



Birth: Seattle, WA; U.S. citizen

Maiden name: Stacey Shiovitz



2000 – 2004                            B.S. (Biology)                            Brandeis University                                                                                                                                                                        Major in Biology with departmental high honors


2004 – 2008                            M.D.                                          University of Michigan Medical School             



2008 2011                            Internal Medicine Residency, University of Michigan                                         

                                                        Research mentor: Dr. Stephen B. Gruber


2011 2014                            Hematology-Oncology Fellowship, University of Washington (UW) &

                                                        Fred Hutchinson Cancer Research Center (FHCRC)                                                                                                  NIH T32 Oncology Research Fellow

                                                        Research mentor: Dr. William M. Grady


                                                        Elective coursework              / workshops                                                                                   

2013 – 2014                            Biostatistics, University of Washington: Medical Biometry I-III

2013 – 2014                            City of Hope Intensive Course in Cancer Genetics

2015              SWOG Integrated Translational Science Center Workshop (June 2015, Cold Spring Harbor, NY)



11/1/14                                          Assistant Professor, Division of Oncology, University of Washington

11/1/14                            Assistant Member, Clinical Research Division, Fred Hutchinson Cancer Research Center



11/1/14                                          Attending Staff, University of Washington Medical Center


Awards and Honors

20002004                            Justice Brandeis Scholar, a four-year merit based scholarship

20002004                            Brandeis University Dean’s List (GPA 3.5 or higher) for all 8 semesters

2004                                          Phi Beta Kappa, Brandeis University

2004                                          Summa Cum Laude, Brandeis University

2005                                          Summer Biomedical Research Fellowship Award

2013                                          Student/Postdoc Advisory Committee (SPAC) Scholarship Award

2013                            FHCRC-nominated applicant for the Association of American Cancer Institutes (AACI) 2014 Translational Research Fellowship

2014                            Young Investigator Award from the Conquer Cancer Foundation of the American Society for Clinical Oncology

2015 – 2016              NIH Loan Repayment Award for Clinical Research

2015                            FHCRC-nominated applicant for the National Comprehensive Cancer Network (NCCN) 2016 Young Investigator Award

2017                            National Clinical Trials Network LAPS Grant travel award



2014                                          Board-certified, Medical Oncology, American Board of Internal Medicine

2014                                          Board-eligible, Hematology

2011                                          Board-certified, Internal Medicine, American Board of Internal Medicine


CURRENT LICENSE(s) to practice

2011                                           Washington state


professional organizations

2011                                          American Society for Clinical Oncology (ASCO), Member

2011 – 2015                             American Society for Hematology (ASH), Member

2013                            American Association for Cancer Research (AACR), Member

2014 –                                          Southwest Oncology Group (SWOG), Member


tEaching responsibilities

2015 –                            Attending physician for the Oncology resident teaching service

                                          University of Washington


2015 –               Continuity clinic mentor for PGY2 pharmacy residents

                                          Seattle Cancer Care Alliance


2016 –               Continuity clinic mentor for Hematology-Oncology senior fellows

                                          Seattle Cancer Care Alliance             


2016                            University of Washington Medical School: M1 oncology course

                                          Small group leader


editorial responsibilities

Ad hoc Journal Article Reviewer

Gut, Gastroenterology, Clinical Cancer Research, Cancer, Carcinogenesis, Nature Communications, Epigenetics, Genetics in Cancer, PLoS One


special national responsibilities

2014                                           SWOG Translational Medicine Committee, Member

2016 –                             Colon Cancer Family Registry, Steering Committee Member

2017                            Conquer Cancer Foundation Scientific and Career Development Retreat, Program Committee Member


special local responsibilities

2013 – 2015              Universal Lynch Syndrome and genetics screening committee

                                          University of Washington and the Seattle Cancer Care Alliance

2014 –                            Lower GI Working Group, UW/SCCA

2014                            Solid Tumor Translational Research (STTR), FHCRC, Colorectal Cancer Research Groups

2015                            Colon and Rectal Cancer Pathways committee

2015                             Colorectal Cancer Specialty Clinic Working Group, UW/SCCA




Active                                                                                                                                               Annual Direct Costs

11/1/16 – 4/30/20              R01-CA196337-02                                                                                    $408,286

                                          Serrated Colorectal Cancer: An Emerging Disease Subtype

                                          Role: Investigator (5% FTE); PI: Polly Newcomb

                                          Source: National Institute of Health / National Cancer Institute

The objective of this project is to characterize factors relating to the genetic predisposition, clinical presentation, and prognosis of serrated colorectal cancer.


2/2017 –                             Clinical trial: “Molecular Analysis for Therapy Choice (MATCH)”/EAY131

                                          Role: Local PI for GI cancers

                                          Sponsor: National Cancer Institute


4/2017 – 3/2018              CCSG/Safeway pilot grant                                                                      $80,000

                            Optimization of therapy for colorectal cancer using a novel functional screen

                            Role: PI (20% FTE)

                            Source: Cancer Consortium of UW/Fred Hutch and Safeway

The objective of this project is to pilot a pipeline of turning generating organoids from genetically-characterized PDX colorectal cancer samples and then evaluate these organoids using a novel functional drug response screen.


4/2017 –                             Clinical trial: “A Phase III Study of BBI-608 (Napabucasin) in Combination with 5-Fluorouracil, Leucovorin, Irinotecan (FOLFIRI) in Adult Patients with Previously Treated Metastatic Colorectal Cancer”

                                          Role: Local PI (5% FTE)

                                          Sponsor: Boston Biomedical


9/2017 –                             Clinical trial: “A Phase II Clinical Trial Platform of Sensitization Utilizing Total Neoadjuvant Therapy (TNT) in Rectal Cancer” (NRG GI002)

                                          Role: Local PI

                                          Sponsor: NRG Oncology



2016 -                                           R01 submission

“Efficacy of Testosterone Replacement Therapy in Hypogonadal Male Cancer Survivors”

                                          Role: Co-Investigator (5% FTE); PI: Jose M Garcia

                                          Source: National Institute of Health

The objective of this project is to evaluate how testosterone supplementation can affect fatigue and other symptoms in survivors of colorectal cancer.


2016 -                                           R01 submission

“Improving Fatigue and Sexual Function in Older Androgen Deficient Men with Cancer”

                                          Role: Co-Investigator (5% FTE); PI: Jose M Garcia

                                          Source: National Institute of Health

The objective of this project is to evaluate how testosterone supplementation can affect fatigue and other symptoms in patients undergoing treatment for colorectal cancer.


Clinical trial: Phase 1 Study of ADI-PEG 20 plus FOLFOX in Subjects with Advanced Gastrointestinal Malignancies

                                          Role: Local PI (5% FTE)

                                          Sponsor: Polaris                                                                                    $TBD



1/1/13 – 10/31/14               T32 Training Grant (5T32CA009515-28/29)                   Full salary support

                            Role: Trainee; PI: Appelbaum

                            Source: National Institute of Health


7/1/14 – 6/30/15              Young Investigator Award                                                                      $47,500

“Identification of host genetic markers and environmental exposures conducive to the development of metastatic colorectal cancer”

                            Role: Principal Investigator

Source: Conquer Cancer Foundation of the American Society for Clinical Oncology


3/1/15 – 2/29/16              U01 CA137088 Program Grant supplement                            $212,027

                                          “Molecular pathological epidemiology of colorectal cancer”

                                          Role: Co-Investigator (5% FTE); PI: Ulrike Peters

                                          Source: National Institute of Health / National Cancer Institute


2016                            Clinical trial: “A Phase II Clinical Trial of Pembrolizumab as Monotherapy and in Combination with Cisplatin+5-Fluorouracil in Subjects with Recurrent or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma (KEYNOTE-059)

                                          Role: Local PI

                                          Sponsor: Merck





ORCID iD 0000-0002-6207-9856



(a) Peer-reviewed journal publications

+Indicates multiple first authors.


  1. Shaag, A, Walsh T, Renbaum P, Kirchhoff T, Nafa K, Shiovitz S, Mandell JB, Welcsh P, Lee MK, Ellis N, Offit K, Levy-Lahad E, and King M-C. (2005). Functional and genomic approaches reveal an ancient CHEK2 allele associated with breast cancer in the Ashkenazi Jewish population. Human Molecular Genetics 14: 555-563.

Role: primary bench research with haplotype sequencing of all included individuals.


  1. *Shiovitz S, Everett J, Huang SC, Gruber SB. (2010). Head Circumference in the Clinical Detection of PTEN Hamartoma Tumor Syndrome in a Clinic Population at High-Risk of Breast Cancer. Breast Cancer Res Treat 124: 459-465.


  1. Mukherjee B, Rennert G, Ahn J, Dishon S, Lejbkowicz F, Rennert HS, Shiovitz S, Moreno V, Gruber SB. (2011). High risk of colorectal and endometrial cancer in Ashkenazi families with the MSH2 A636P founder mutation. Gastroenterol 140: 191-1926.

Role: database quality control and clean-up


  1. Shiovitz S, Gay A, Morris A, Graff JJ, Katz SJ, Hawley ST. (2011). Dissemination of Quality-of-Care Research Findings to Breast Oncology Surgeons. J Onc Practice 7: 257-262.


  1. Shiovitz S and Eaton KD. (2012). A 66-year-old woman with newly diagnosed oligometastatic non-small cell lung cancer. JNCCN 10: 297-301.


  1. *Shiovitz S+, Bertagnolli MM+, Renfro LR, Nam E, Foster NR, Dzieciatkowski S, Luo Y, Lao VV, Monnat RJ, Emond MJ, Maizels N, Niedzwiecki D, Goldberg RM, Saltz LB, Venook A, Warren RS, Grady WM. (2014). CpG Island Methylator Phenotype is Associated With Response to Adjuvant Irinotecan-Based Therapy for Stage 3 Colon Cancer. Gastroenterol 147(3) 637-645.

Role: led the data analysis and was the primary writer of the manuscript


  1. *Shiovitz S, Copeland WK, Newcomb PA, Passarelli MN, Burnett-Hartman AN, Buchanan D, Gallinger S, Haile R, Le Marchand L, Grady WM, Lindor NM for the Colorectal Cancer Family Registry. (2014). Characterization of Familial Colorectal Cancer Type X, Lynch syndrome, and non-familial colorectal cancer. Brit J Cancer 111(3): 598-602.


  1. Shiovitz S and Korde LA. (2015). Genetics of Breast Cancer: A Topic in Evolution. Ann Oncol. 26(7) 1291-1299.

Tables reproduced in “Mentoring Cancer Genomics in Primary Care, Module 9: Future Directions in Cancer Genomics.” Supported by the Connecticut Department of Public Health-Genomics Office with funding provided by Centers for Disease Control and Prevention Cooperative Agreement #DP5355-02


  1. Shiovitz S and Grady WM. (2015). Molecular Markers Predictive of Chemotherapy Response in Colorectal Cancer. Curr Gastroenterol Rep 17(2): 431.


  1. Shiovitz S, Bansal A, Burnett-Hartman AN, Karnopp A, Adams SV, Warren-Mears V, and Ramsey SD. (2015). Cancer-directed therapy and hospice care for metastatic cancer in American Indians and Alaska Natives. Cancer Epidemiol Biomarkers Prev. 24(7):1138-43.

Abstract: ASCO Annual Meeting. June 2014. Chicago, IL.


  1. Kocarnik JM+, Shiovitz S+, and Phipps AI. (2015). Molecular Phenotypes of Colorectal Cancer and Potential Clinical Applications. Gastroenterol Rep. 3(4): 269-276.


  1. Cohen SA+, Wu C+, Yu M, Gourgioti G, Wirtz R, Raptou G, Gkakou C, Kotoula V, Pentheroudakis G, Papaxoinis G, Karavasilis V, Pectasides D, Kalogeras KT, Fountzilas G, and Grady WM. (2015). Evaluation of CpG Island Methylator Phenotype as a biomarker in colorectal cancer treated with adjuvant oxaliplatin. Clin Colorect Cancer. 15(2): 164-169.

Abstract: Gastrointestinal Cancers Symposium. January 2015. San Francisco, CA.


  1. Woo J, Cohen SA, and Grim JE. (2015). Targeted therapy in gastroesophageal cancers: past, present and future. Gastroenterol Rep. 3(4): 316-329.


  1. *Cohen SA, Laurino M, Bowen DJ, Upton M, Pritchard C, Hisama F, Jarvik G, Fichera A, Sjoding B, Bennett R, Naylor L, Jacobson A, Burke W, and Grady WM. (2015). Initiation of universal tumor screening for Lynch syndrome in colorectal cancer patients as a model for the implementation of genetic information into clinical oncology practice. Cancer. 122 (3): 393-401.

Abstract: Oncology Recognition Day. June 2014. Seattle, WA.


  1. Levine, AJ, Phipps AI, Baron JA, Buchanan DB, Ahnen DJ, Cohen SA, Lindor NL, Newcomb PA, Rosty C, Haile RW, Laird RW, and Weisenberg DJ. (2016). Clinicopathological risk factor distributions for MLH1 promoter region methylation in CIMP positive tumors. Cancer Epidemiol Biomarkers Prev. 25(1): 68-75.


  1. Adams SV, Burnett-Hartman AN, Karnopp A, Bansal A, Cohen SA, Warren-Mears V, and Ramsey SD. (2016). Cancer Stage in American Indians and Alaska Natives enrolled in Medicaid. Am J Prev Med. 51(3): 368-72


  1. Adams SV, Bansal A, Burnett-Hartman AN, Cohen SA, Karnopp A, Korenbrot C, Warren-Mears V, and Ramsey SD. (2016). Cancer Treatment Delays in American Indians and Alaska Natives Enrolled in Medicare. J Health Care Poor Underserved. 51(3): 368-372.

Abstract: ASCO Annual Meeting. June 2014. Chicago, IL.


  1. *Cohen SA+, Turner EH+, Beightol MB, Jacobson A, Gooley TA, Salipante SJ, Haraldsdottir S, Smith C, Scroggins S, Tait JF, Grady WM, Lin EH, Cohn DE, Goodfellow PJ, Arnold W, de la Chapelle A, Pearlman R, Hampel H, and Pritchard CC. (2016). Frequent PIK3CA Mutations in Colorectal and Endometrial Cancer with Double Somatic Mismatch Repair Mutations. Gastroenterol 151(3): 440-447.

Role: led the data analysis and was the primary writer of the manuscript; Abstract: ASCO Annual Meeting. June 2015. Chicago, IL.


  1. Burnett-Hartman AN, Adams SV, Bansal A, McDougall JA, Shiovitz SA, Karnopp A, Warren-Mears V, and Ramsey SD. (2016). Indian Health Service Care System and Cancer Stage in American Indians and Alaska Natives. J Health Care Poor Underserved. In Press.


  1. Robinson JR, Newcomb PA, Hardikar S, Cohen SA, and Phipps AI. (2017). Stage IV colorectal cancer primary site and patterns of distant metastasis. Cancer Epidemiol 48: 92-95.


  1. Cohen SA+, Yu M+, Baker K, Redman M, Wu C, Heinzerling TJ, Wirtz RM, Charalambous E, Pentheroudakis G, Kotoula V, Kalogeras KT, Fountzilas G, Grady WM. (2017). The CpG Island Methylator Phenotype Is Concordant Between Primary Colorectal Carcinoma and Matched Distant Metastases. Clin Epigenetics 48: 92-95.


  1. Hua X, Phipps AI, Burnett-Hartman A, Adams SV, Hardikar S, Cohen SA, Kocarnik J, Ahnen DJ, Lindor NM, Baron JA, and Newcomb PA. (2017). Timing of aspirin and other non-steroidal anti-Inflammatory drug use among colorectal cancer patients in relation to tumor markers and survival. J Clin Oncol 35: 2806-2813.


  1. Kocarnik JM, Hua X, Hardikar S, Robinson J, Lindor NM, Win AK, Jopper J, Figueiredo JC, Potter JD, Campbell PT, Gallinger S, Cotterchio M, Adams SV, Cohen SA, Phipps AI, and Newcomb PA. (2017). Long-term weight loss after colorectal cancer diagnosis is associated with lower survival: the Colon Cancer Family Registry. Cancer: Epub ahead of print. doi: 10.1002/cncr.30932.



(b) Book chapters



(c) Published books, videos, software, etc.



(d) Other publications

1.      King M-C, Marks JH, and Mandell JB. (2003) Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2. Science 302: 643-646.

Role: acknowledged for contributing bench research as part of the New York Breast Cancer Study Group


2.      Shiovitz S. (2004). The negative effect between oncogenic Ras and STAT5 in leukemogenesis [honors thesis]. Brandeis University, Waltham, MA.


(e) Manuscripts submitted

  1. Hyams T, Bowen D, Cohen SA, Laurino MY, Bennett RL, Jarvik GP, and Burke W. Patients and Providers Experience with the Implementation of Universal Screening for Lynch Syndrome at the Seattle Cancer Care Alliance.


  1. Schirippa M+, Cohen SA+, Battaglin F, and Lenz HJ. Biomarker-Driven and Molecular Targeted Therapies for Colorectal Cancers. Sem Oncol Rev.


(f) Abstracts (selected, not otherwise represented above)

  1. Shiovitz S, Grady WM. DCC and RET pathway analysis to identify factors associated with advanced colorectal cancer. Gastrointestinal Cancers Symposium. January 2014. San Francisco, CA.


  1. Laurino M, Shiovitz S, Burnett-Hartman AN, Bennett R, Brentnall T, Hisama F, Jacobson A, Jarvik A, Neufeld-Kaiser W, Sjoding B, Steinbach G, Swisher E, Newcomb PA, Grady WM. Ten Years of Experience of a High-Risk Gastrointestinal Multidisciplinary Clinic. American College of Medical Genetics Annual Clinical Genetics Meeting. March 2014. Nashville, TN.


  1. Hyams T, Laurino MY, Bowen D, Cohen SA, Grady WM, Miller M, and Burke W. Views of Patients Regarding Lynch Syndrome Screening. American Society for Human Genetics. October 2015. Baltimore, MD.


  1. Cohen SA, Qu C, Harrison TA, Hsu L, Newcomb PA, Gruber SB, Berndt SI, Bezieau S, Casey G, Chan AT, Chang-Claude J, Slattery ML, White E, Vargas AJ, Nassir R, Peters U, Grady WM, on behalf of the GECCO consortium. Assessment of candidate host “progression genes” in the development of advanced colorectal cancer. American Association for Cancer Research. April 2016. New Orleans, LA.


  1. Chang AE, Shahada S, Harris WP, Cohen SA, Coveler AL, O’Neil B, Gadi VK, Hibbert R, Lee HE, Youngner A, McCormick KA, Pritchard CC, Redman MW, Chiorean EG. Phase I/IB multicenter study of afatinib in combination with capecitabine in patients (pts) with refractory solid tumors and pancreatico-biliary cancers. Gastrointestinal Cancers Symposium. January 2017. San Francisco, CA.


  1. Torti E, Park JO, Chiorean EG, Kim EY, Cohen SA, Coveler AL. Retrospective review of outcomes in patients (pts) with synchronous metastatic rectal cancer (mRC) receiving initial non-surgical management. Gastrointestinal Cancers Symposium. January 2017. San Francisco, CA.

OTHER (National invitational lectures)


2017              Invited speaker: 2017 American Society for Colon & Rectal Surgeons (ASCRS) Tri-partite Annual Scientific Meeting, June 2017, Seattle, WA

              Unexpected intraoperative carcinomatosis in a minimally symptomatic patient: what is the best treatment?”


Invited panelist: Tri-Cancer Outreach Event, co-sponsored by PanCAN, ACS, Rivkin Center, Susan G. Komen

              April 2017; Mercer Island, WA


              Invited speaker: Seattle Cancer Care Alliance (SCCA) outreach talks              Emerging Therapies in Colorectal Cancer

              February 2017; Puyallup, WA


2016              Discussant: Cases from Kampala: Colorectal Cancer. October 2016, Seattle, WA and Kampala, Uganda.


              Invited speaker: SCCA Comprehensive Hematology & Oncology Review Course, September 2016, Seattle WA

              “Colorectal Cancer”


              Lecturer/Discussant: SCCA Network Tumor Board, Boise ID


2015              Invited speaker: Seattle Cancer Care Alliance (SCCA) outreach talks              Emerging Therapies in Colorectal Cancer

Anchorage, AK; Tri-cities, WA, Tacoma, WA; Bend, OR